|
| Effect of Guben Jiedu Quyu prescription with chemotherapy on the NSCLC |
| Hits 1621 Download times 1342 Received:January 21, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2017.05.10 |
| Key Words
Guben Jiedu Quyu;non-small cell lung cancer;effect |
| Author Name | Affiliation | | ZHANG Fu-liang | Tianjin Nankai Hospital, Tianjin 300100, China | | KONG Fan-ming | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | LI Dong-sheng | Tianjin Nankai Hospital, Tianjin 300100, China | | HU Guo-hua | Tianjin Nankai Hospital, Tianjin 300100, China | | XU Tong-bai | Tianjin Nankai Hospital, Tianjin 300100, China | | QIAO Man | Tianjin Nankai Hospital, Tianjin 300100, China | | CHEN Yan-hua | Tianjin Nankai Hospital, Tianjin 300100, China | | CHI Hang | Tianjin Nankai Hospital, Tianjin 300100, China |
|
| Abstract
|
| [Objective] To investigate the effect of Guben Jiedu Quyu prescription with chemotherapy on the non-small cell lung cancer (NSCLC).[Methods] Total of 80 NSCLC patients who received treatment were enrolled. The patients were divided into two groups based on the treatment. Forty patients in control group were received chemotherapy and forty patients in treatment group were received chemotherapy and Guben Jiedu Quyu prescription. The blood routine examination, peripheral blood T lymphocyte subsets, and Karnofsky Performance Scores (KPS) were compared between two groups.[Results] The blood WBC, HGB and PLT were significantly decreased in the treatment group and the control group after treatment (P<0.05), While the control group was more significantly decreased than the treatment group (P>0.05). For the peripheral blood T lymphocyte subsets, the CD3+、CD4+、CD4+/CD8+ were all increased in the treatment group(P<0.01), while the CD3+ was decreased in the control group(P<0.05). The KPS was also improved in the experiment group (P<0.05).[Conclusion] Guben Jiedu Quyu prescription can reduce bone marrow suppression of chemotherapy, enhance immune function and improve the quality of life of NSCLC patients. |
|
|
|
|
|
|
|
